LAS VEGAS—A novel multivitamin antioxidant nutraceutical may be useful in the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients, data suggest.
Amit Sharma, MD, and his collaborators at the Boise Kidney and Hypertension Institute in Meridan, Idaho, tested the product, trademarked MV-ONE, in 25 HD patients in an open-label, non-blinded, non-randomized single-site study. Patients took the multivitamin once daily with food for 12 weeks. The product, which is made by Nephrian Inc., of Thousand Oaks, Calif., contains cholecalciferol 1500 IU, gamma-tocopherol 300 mg, and alpha lipoic acid 600 mg. Nephrian sponsored the study.
MV-ONE treatment significantly increased 25-hydroxyvitamin levels by a mean of 33% and significant decreased epoetin alfa dosing by a mean of 34%, according to findings presented at the National Kidney Foundation’s Spring Clinical Meetings.
Continue Reading
The researchers stated that the nutraceutical increases active vitamin D blood levels in HD patients, thus identifying its efficacious ability to potentiate treatment for SHPT. By decreasing requirements for erythropoiesis-stimulating agents, it could aid in treating anemia stemming from renal disease.
The antioxidative properties of the nutraceutical “may be a useful cost-effective adjuvant in an increasingly challenging clinical environment,” the authors concluded.
